Cytely raises €3M as smart microscopy transforms lab analysis

European laboratories are embracing AI-powered microscopy at unprecedented rates, with productivity gains of up to 75% driving investment across the continent. This surge in digitalisation reflects broader trends in MedTech automation as regulatory frameworks like the EU’s Medical Device Regulation create demand for more precise, traceable diagnostic tools.

Swedish biotech Cytely has secured €3 million in funding to accelerate its smart microscopy platform across European markets. The round was led by Ugly Duckling Ventures, positioning the Stockholm-based company to capitalise on growing demand for AI-enhanced laboratory equipment.

Founded in 2021, Cytely has developed automated microscopy solutions that reduce analysis time whilst improving accuracy in cellular research. The company’s platform combines advanced imaging with machine learning algorithms to streamline workflows for pharmaceutical research and clinical diagnostics.

Smart microscopy funding attracts Nordic investors

Ugly Duckling Ventures, known for backing early-stage Nordic deeptech companies, led the investment round. The Stockholm-based VC has previously invested in companies like Kognic and Recorded Future, demonstrating their commitment to AI-powered solutions with global potential.

“We’re seeing laboratories across Europe struggling with bottlenecks in microscopy analysis,” explains a spokesperson from Ugly Duckling Ventures. “Cytely’s approach of combining hardware optimisation with intelligent software creates compelling value for research institutions facing increasing workloads.”

The funding positions Cytely within a growing ecosystem of Nordic companies applying AI to traditional industries. Sweden’s strong research infrastructure and talent pipeline in both life sciences and artificial intelligence create natural advantages for companies like Cytely competing in global markets.

European investors are increasingly focused on companies that can demonstrate clear productivity improvements in regulated industries, particularly where AI adoption has lagged behind other sectors.

European laboratories drive adoption of automated microscopy

Cytely’s platform addresses specific challenges within European research environments, where varying regulatory requirements across member states create complexity for traditional microscopy workflows. The company’s automated approach helps standardise analysis protocols whilst maintaining compliance across different jurisdictions.

“Traditional microscopy requires extensive manual intervention, creating variability in results,” notes Cytely’s leadership team. “Our platform ensures consistent, reproducible analysis whilst dramatically reducing time-to-insight for research teams.”

The funding will support expansion across key European markets, including Germany’s pharmaceutical research sector and the UK’s biotech clusters. Cytely plans to establish partnerships with major research institutions whilst developing additional AI capabilities for specialised microscopy applications.

Competition in the automated microscopy space includes established players like Leica Microsystems and emerging AI-first companies. However, Cytely’s focus on European regulatory requirements and local partnership strategies provides differentiation in fragmented markets.

This investment reflects growing confidence in Nordic deeptech companies that combine hardware innovation with AI capabilities. As European laboratories face increasing pressure to improve efficiency whilst maintaining quality standards, solutions like Cytely’s platform become increasingly attractive for research institutions and commercial laboratories alike.